PTLD, an aggressive lymphoma in transplant recipients, affects up to 20% of high-risk patients with a 60% two-year mortality.

Primarily driven by EBV reactivation after immunosuppression (occurs in up to 60% of recipients).

Current SoC reduces immunosuppression to control EBV, increasing the risk of graft rejection and life-threatening complications

ABV-010 is a potent antibody that targets a uniquely vulnerable site on the EBV entry protein. 

In preclinical models, ABV-010 completely blocks EBV infection and prevents PTLD development.

By stopping PTLD before it starts, ABV-010 enables physicians to maintain immunosuppression, preserving graft integrity and transforming transplant outcomes.

There are more than 125,000 transplants performed each year across the US and Europe, with annual growth of about 5%. 

An estimated 27,000 patients are at high risk for developing PTLD.

AbVir’s approach can help mitigate these risks with a low predicted side-effect profile.